文献速递乳腺癌

化疗与多合并症老年ER阳性淋巴结阳性乳腺癌患者生存的关联

Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.
PubMed 文献 · JAMA Oncol · 2020-01-01

该回顾性队列研究纳入美国国家癌症数据库中1592例70岁以上、Charlson/Deyo合并症评分2或3分、雌激素受体阳性且ERBB2阴性、病理淋巴结阳性的乳腺癌术后患者。

要点

  • 多合并症老年淋巴结阳性ER阳性乳腺癌患者接受辅助化疗与总生存改善相关。
  • 匹配队列中化疗组与未化疗组中位总生存差异未达统计学意义。
  • 化疗组患者更年轻、肿瘤更大、淋巴结负荷更高且更多接受内分泌和放疗。

核心结论

  • 在淋巴结阳性、雌激素受体阳性且伴多重合并症的老年乳腺癌患者中,接受化疗与总生存改善相关。
  • 尽管尝试校正选择偏倚,医生可能基于未测量变量仔细选择了可能从辅助化疗获益的患者。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2010年1月1日至2014年12月31日数据。
  • 纳入70岁及以上、Charlson/Deyo合并症评分2或3分、雌激素受体阳性且ERBB2阴性、病理淋巴结阳性并接受手术的患者。
  • 共1592例患者纳入初始非匹配分析,平均(SD)年龄77.5(5.5)岁,1543例(96.9%)为女性。
  • 采用倾向评分基于年龄、合并症评分、机构类型、机构位置、病理T和N分期及辅助内分泌和放疗 receipt 进行匹配。

主要发现

  • 350例(22.0%)接受化疗,1242例(78.0%)未接受化疗。
  • 化疗组较未化疗组更年轻(平均年龄74 vs 78岁,P<.001)、原发肿瘤更大(pT3/T4:72例[20.6%] vs 182例[14.7%],P=.005)。
  • 化疗组病理淋巴结负荷更高(pN3:75例[21.4%] vs 81例[6.5%];pN1:182例[52.0%] vs 936例[75.4%],P<.001)。
  • 化疗组更多接受内分泌治疗(309例[88.3%] vs 1025例[82.5%],P=.01)和放疗(236例[67.4%] vs 540例[43.5%],P<.001)。
  • 匹配队列中位随访43.1个月(95%CI 39.6-46.5个月),化疗组与未化疗组中位总生存分别为78.9个月(95%CI 78.9个月至未达到)和62.7个月(95%CI 56.2个月至未达到),P=.13。

关键数值与推荐

  • 多因素调整后,化疗与总生存改善相关(HR 0.67,95%CI 0.48-0.93,P=.02)。

临床怎么用

  • 对多合并症老年淋巴结阳性ER阳性乳腺癌患者,辅助化疗可能改善生存,但需仔细选择患者。
  • 建议采用标准化的多学科诊疗方法,可能与该人群长期治疗结局相关。

局限性

  • 回顾性队列设计,存在选择偏倚可能,即使采用倾向评分匹配和多重调整。
  • 医生可能基于未测量变量选择患者,导致残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Breast cancer risk and comorbidities increase with age. Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer. OBJECTIVE: To examine the association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients in the US National Cancer Database who were 70 years or older; had a Charlson/Deyo comorbidity score of 2 or 3; had estrogen receptor-positive, ERBB2 (formerly HER2 or HER2/neu)-negative breast cancer; and underwent surgery for pathologic node-positive breast cancer from January 1, 2010, to December 31, 2014. Propensity scores were used to match patients receiving adjuvant chemotherapy with those not receiving adjuvant chemotherapy based on age, comorbidity score, facility type, facility location, pathologic T and N stage, and receipt of adjuvant endocrine and radiation therapy. Data analysis was performed from December 13, 2018, to April 28, 2020. EXPOSURES: Chemotherapy. MAIN OUTCOMES AND MEASURES: The association of adjuvant chemotherapy with overall survival was estimated using a double robust Cox proportional hazards regression model. RESULTS: Of a total of 2 445 870 patients in the data set, 1592 patients (mean [SD] age, 77.5 [5.5] years; 1543 [96.9%] female) met the inclusion criteria and were included in the initial nonmatched analysis. Of these patients, 350 (22.0%) received chemotherapy and 1242 (78.0%) did not. Compared with patients who did not receive chemotherapy, patients who received chemotherapy were younger (mean age, 74 vs 78 years; P < .001), had larger primary tumors (pT3/T4 tumors: 72 [20.6%] vs 182 [14.7%]; P = .005), and had higher pathologic nodal burden (75 [21.4%] vs 81 [6.5%] with stage pN3 disease and 182 [52.0%] vs 936 [75.4%] with stage pN1 disease; P < .001). More patients who received chemotherapy also received other adjuvant treatments, including endocrine therapy (309 [88.3%] vs 1025 [82.5%]; P = .01) and radiation therapy (236 [67.4%] vs 540 [43.5%]; P < .001). In the matched cohort, with a median follow-up of 43.1 months (95% CI, 39.6-46.5 months), no statistically significant difference was found in median overall survival between the chemotherapy and no chemotherapy groups (78.9 months [95% CI, 78.9 months to not reached] vs 62.7 months [95% CI, 56.2 months to not reached]; P = .13). After adjustment for potential confounding factors, receipt of chemotherapy was associated with improved survival (hazard ratio, 0.67; 95% CI, 0.48-0.93; P = .02). CONCLUSIONS AND RELEVANCE: This cohort study found that in node-positive, estrogen receptor-positive elderly patients with breast cancer and multiple comorbidities, receipt of chemotherapy was associated with improved overall survival. Despite attempts to adjust for selection bias, these findings suggest that physicians carefully selected patients likely to derive treatment benefit from adjuvant chemotherapy based on certain unmeasured variables. A standardized, multidisciplinary approach to care may be associated with long-term treatment outcomes in this subset of the population.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tamirisa N, Lin H, Shen Y, et al. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. JAMA Oncol. 2020. PMID: 32672820. doi:10.1001/jamaoncol.2020.2388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。